Omicia and LabCorp Collaborate on Integrated Platform for Genomic Analysis in Clinical Trials
Omicia, Inc. announced that its clinical next-generation sequencing interpretation software will be used by LabCorp.
Omicia, Inc. announced that its clinical next-generation sequencing (NGS) interpretation software will be used by LabCorp® for its clinical trials sequencing services, to offer clients a comprehensive suite of expert tools and services for incorporating genomic data into clinical trials.
The Omicia/LabCorp collaboration addresses the growing demand for NGS-derived biomarker data. This effort also highlights LabCorp’s continued focus on biomarker development to support clinical trial activities. The collaboration will enable customers of both companies to integrate NGS data into clinical trials in a more streamlined way.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
